Clinical Trials
50 trialsNCT05642195 2026-05-27
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT06876142 2026-05-27
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT02130492 2026-05-15
A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)
Weill Medical College of Cornell University
Phase 1/2 Suspended
NCT05200442 2026-05-08
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
University of Chicago
Phase 1/2 Suspended
NCT05435014 2026-04-14
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
T-ACE Medical Co., Ltd
Phase 1/2 Suspended
NCT05322850 2026-04-13
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
University of Florida
Phase 1/2 Suspended
NCT04908111 2026-04-06
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Phase 1/2 Suspended
NCT04278768 2026-03-19
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Curis, Inc.
Phase 1/2 Suspended
NCT04890093 2026-03-16
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Suspended
NCT06219174 2026-03-06
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Suspended
NCT05419479 2026-02-24
Switch Maintenance in Pancreatic
Dana-Farber Cancer Institute
Phase 1/2 Suspended
NCT05000294 2026-02-18
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
University of Florida
Phase 1/2 Suspended
NCT06211933 2026-02-12
PULS
Centre Leon Berard
Phase 1/2 Suspended
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT04855253 2026-01-15
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
Masonic Cancer Center, University of Minnesota
Phase 1/2 Suspended
NCT04677049 2026-01-02
Study of Niacin in Glioblastoma
AHS Cancer Control Alberta
Phase 1/2 Suspended
NCT03417921 2025-10-01
Pancreatic
Ability Pharmaceuticals SL
Phase 1/2 Suspended
NCT03384836 2025-07-02
Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Suspended
NCT05603572 2025-06-05
KAT-101 in Subjects With Hepatocellular Carcinoma (HCC)
Primocure Pharma
Phase 1/2 Suspended
NCT01386710 2025-04-09
Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma
Northwell Health
Phase 1/2 Suspended
NCT05669352 2025-04-04
A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases
University of Florida
Phase 1/2 Suspended
NCT03187210 2025-03-30
BAL
Insel Gruppe AG, University Hospital Bern
Phase 1/2 Suspended
NCT06643494 2025-03-11
Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical
Optimal Health Research
Phase 1/2 Suspended
NCT05416749 2024-11-20
A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2 Suspended
NCT06147505 2024-10-29
XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)
Dushu Lake Hospital Affiliated to Soochow University
Phase 1/2 Suspended
NCT04946864 2024-08-19
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Ascentage Pharma Group Inc.
Phase 1/2 Suspended
NCT03181035 2024-08-12
FAITH
Sunnybrook Health Sciences Centre
Phase 1/2 Suspended
NCT05101616 2024-03-07
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
Shanghai Minimally Invasive Surgery Center
Phase 1/2 Suspended
NCT05168904 2024-02-08
A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Suspended
NCT04505813 2024-01-16
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma
NexImmune Inc.
Phase 1/2 Suspended
NCT04558684 2024-01-03
Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2 Suspended
NCT05138458 2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2 Suspended
NCT04485052 2023-10-23
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2 Suspended
NCT01933815 2023-02-22
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
Cortice Biosciences, Inc.
Phase 1/2 Suspended
NCT03208296 2023-02-06
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
Ascend Biopharmaceuticals Ltd
Phase 1/2 Suspended
NCT04042116 2022-12-20
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Clovis Oncology, Inc.
Phase 1/2 Suspended
NCT03704714 2022-08-15
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Northwestern University
Phase 1/2 Suspended
NCT02910752 2021-11-26
CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation
Shanghai Jiao Tong University School of Medicine
Phase 1/2 Suspended
NCT01562626 2021-05-12
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
Anaeropharma Science, Inc.
Phase 1/2 Suspended
NCT01627795 2018-04-18
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Oshadi Drug Administration
Phase 1/2 Suspended
NCT02026362 2017-10-18
HCC DC CTL
HRYZ Biotech Co.
Phase 1/2 Suspended
NCT01929239 2016-06-17
Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning
Roger Williams Medical Center
Phase 1/2 Suspended
NCT01211691 2015-11-17
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Humanigen, Inc.
Phase 1/2 Suspended
NCT01226056 2010-10-21
Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets
Southern Europe New Drug Organization
Phase 1/2 Suspended
NCT00209729 2010-05-26
Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Suspended
NCT01122342 2010-05-13
Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.
University of Vermont
Phase 1/2 Suspended
NCT00637364 2009-01-13
HIFU Pancreas
CMED HIFU Development Corporation
Phase 1/2 Suspended
NCT00443573 2008-05-07
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
ARCA Biopharma, Inc.
Phase 1/2 Suspended
NCT00209677 2007-11-01
Phase I/II Study of Oral S-1 Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Hokkaido Gastrointestinal Cancer Study Group
Phase 1/2 Suspended
NCT00033956 2005-06-24
Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2
MetaPhore Pharmaceuticals
Phase 1/2 Suspended